Target intelligence / Profile preview

Beta-hematin (BH)

Target
BH
Molecular classification
Biocrystal, Porphyrin polymer, Other
01

Overview

Beta-hematin is the synthetic analogue of hemozoin, a dark-brown biocrystal produced by hematophagous parasites such as Plasmodium falciparum to detoxify free heme. During the intraerythrocytic stage of malaria, the parasite digests host hemoglobin, releasing large quantities of toxic ferriprotoporphyrin IX (heme). To prevent oxidative damage and membrane disruption, the parasite sequesters this heme into insoluble beta-hematin crystals within its acidic food vacuole. This crystallization process is a critical survival mechanism and serves as a primary target for several classes of antimalarial drugs, most notably the quinolines. Drugs like chloroquine bind to the growing faces of the crystals or to free heme, preventing further polymerization and resulting in the accumulation of toxic heme that kills the parasite. Understanding the formation of beta-hematin is essential for developing new treatments against drug-resistant malaria strains.

Other names
HemozoinMalaria pigmentFerriprotoporphyrin IX dimerβ-hematinSynthetic hemozoin
02

Mechanism of action

Inhibition of heme crystallization into beta-hematin, leading to the accumulation of toxic free ferriprotoporphyrin IX which causes parasite cell death.

03

Biological functions

Heme detoxificationSequestration of toxic metabolitesOther
04

Disease associations

InfectionMalariaSchistosomiasis
05

Safety considerations

Drug resistance (e.g., PfCRT and PfMDR1 mutations)Off-target effects of quinoline drugs (e.g., QT prolongation)Hemolytic anemia in G6PD-deficient populationsRetinopathy with long-term use
06

Interacting drugs

7 more in the full profile.

07

Biomarkers

Hemozoin levelsParasitemiaIntraerythrocytic pigment

Beyond the preview

Go deeper on Beta-hematin (BH).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beta-hematin (BH).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call